StemCell Therapy

Cyndi Williams, CEO of diabetes-focused tech start-up Quin, discusses career paths, company culture and her exceptional co-founder.

Cyndi Williams is the co-founder and CEO of Quin, an app designed to help people with diabetes keep track of their insulin.

The app works with data logged into a mobile device, along with continuous glucose monitoring (CGM) devices, to enable people with diabetes to recognise patterns and rely less on trial and error when it comes to insulin administration.

The question that were focused on at Quin is how much insulin a person should take and when, Williams told Siliconrepublic.com. Thats a question that millions of people with insulin-treated diabetes need to answer several times a day, and no one knows the exact answer.

Williams explained that most people with diabetes have to figure out the answer to that question every day, making important healthcare decisions using their own intuition and knowledge of experience.

The goal is to formalise the knowledge of Quin users, with the aim of contributing that data to diabetes research in order to advance personalised medicine for insulin-treated diabetes.

From left: Vanessa Bolosier and Isabella Degen. Image: Quin

We made a mobile app that takes data from existing CGM devices for diabetes, which is a sensor often worn on the arm to measure blood glucose. People also use insulin pens or syringes to inject insulin, and all of our users use an iPhone, Williams said.

We take data off of those devices, we take their activity data from their phone, and we use it to observe and learn how each individual is doing their trial and error on a day-to-day basis as they are going about their lives, and give them advice in the moment they need it, based on their past experience.

One example she gave was ordering a coffee. You may have drank hundreds of lattes in your life and dosed anywhere from zero to five units for lattes. How much should you take for this latte?

Quin would look at how long you slept for last night, how active you have been in the past 24 hours, what insulin you have onboard already, where you are in your menstrual cycle and how you feel in terms of stress.

We look at all of those factors and things that are affecting you, and we go into your past and find the latte decision that is most relevant for you and most closely matches your current situation, then give that to you as the basis for making your decision.

London-based Quin was founded in 2014, but how did Williams end up in the world of diabetes tech?

It was a couple of things, but mainly my interest in Isabella Degen, my co-founder. My background is in chemical engineering and software engineering, but Ive been on the business side of engineering for the last 15 years.

Prior to setting up Quin, Williams worked at Sun Microsystems before becoming a managing director at software and services business ThoughtWorks. This is where she met Degen, also an engineer, whose own diabetes had inspired a potential business idea.

At the time I didnt know anything about diabetes, Williams said. I didnt even know she had diabetes! I just knew how exceptional she was and she was looking for someone to help her set up a business.

Williams added that she was excited to solve a human problem with technology, and that the whole idea tickled the nerve of the engineer within her. Its also a dream to be able to do something that could actually make a material difference to peoples lives.

From left: Cyndi Williams and Isabella Degen. Image: Quin

With an official launch planned for later this year, Quin has been developed behind closed doors for the last two years as part of a research programme with around 100 people who have been providing feedback, ideas and thoughts on the design.

We are a regulated medical device company, Williams said. Every release of our app is a regulated medical device that is released and pushed out to our market. We want to do a human-centred co-creation of a medical device, while also ensuring that what we are doing is safe, will not hurt anyone and will improve the lives of users.

As part of that, we do regular self-reported results from our users and look at three categories of metrics, which are quality of life improvements, medical benefits and behavioural changes that people make.

We have had 76pc of our users reporting that they feel more confident, relaxed and that life with diabetes is easier, from the quality of life point of view. Thats something were very proud of. Its critical as a software product maker that youve got to make a material difference to peoples quality of life.

Aside from tech and engineering, one area of business that Williams is particularly interested in is workplace culture. She spent much of her time in leadership roles at ThoughtWorks coming up with the values, living the values and leading by the values.

What were doing now, our mission is very human-centred and is about making life better for potentially millions of people, she explained. Its really about the values that you put underneath that. For us, our values are quite simple: be excellent, find truth and show love.

The Quin team. Image: Quin

For us, excellence is your interest in collaborating across the areas of the discipline and your ability to draw people in and take people with you on that journey, Williams added.

Finding truth is about the fact that we know so little about diabetes, as well as being willing to throw away our truths when we have to and the problem-solving nature of who we are as people.

The third value is to show love, which is about the space that we live in. Because diabetes is so poorly understood, theres a lot of hurt that happens to people who are living with diabetes. It starts with love for the people we are creating for and working with, but it extends to love for your colleagues.

Although a launch is upcoming, Williams said that the mission of Quin could take 10 years or more. This is hard work certainly the hardest work of my life and the lives of many people who work here. We have to have an unconditional positive regard for each other and really be willing to walk in each others shoes.

To ensure that Quin hires the right people, Williams said that she selects interviewees based on their technical skills as well as their affinity to those values. She added that she asks some pretty pointed questions during the interview process to ensure that new hires share those values.

Its about living those values when were inside and what we do every day and how we behave. It matters. Isabella and I have only ever been in value-based organisations, so if you grow up with it, its sort of second nature.

Want stories like this and more direct to your inbox? Sign up forTech Trends, Silicon Republics weekly digest of need-to-know tech news.

The rest is here:
Cyndi Williams on tech for diabetes and 'showing love' at work - Siliconrepublic.com

This article was originally published here

Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol.

BMJ Open. 2020 Mar 12;10(3):e033500

Authors: Boughton C, Allen JM, Tauschmann M, Hartnell S, Wilinska ME, Musolino G, Acerini CL, Dunger PD, Campbell F, Ghatak A, Randell T, Besser R, Trevelyan N, Elleri D, Northam E, Hood K, Scott E, Lawton J, Roze S, Sibayan J, Kollman C, Cohen N, Todd J, Hovorka R, CLOuD Consortium

AbstractINTRODUCTION: Management of newly diagnosed type 1 diabetes (T1D) in children and adolescents is challenging for patients, families and healthcare professionals. The objective of this study is to determine whether continued intensive metabolic control using hybrid closed-loop (CL) insulin delivery following diagnosis of T1D can preserve C-peptide secretion, a marker of residual beta-cell function, compared with standard multiple daily injections (MDI) therapy.METHODS AND ANALYSIS: The study adopts an open-label, multicentre, randomised, parallel design, and aims to randomise 96 participants aged 10-16.9 years, recruited within 21 days of diagnosis with T1D. Following a baseline mixed meal tolerance test (MMTT), participants will be randomised to receive 24 months treatment with conventional MDI therapy or with CL insulin delivery. A further 24-month optional extension phase will be offered to all participants to continue with the allocated treatment. The primary outcome is the between group difference in area under the stimulated C-peptide curve (AUC) of the MMTT at 12 months post diagnosis. Analyses will be conducted on an intention-to-treat basis. Key secondary outcomes are between group differences in time spent in target glucose range (3.9-10 mmol/L), glycated haemoglobin (HbA1c) and time spent in hypoglycaemia (<3.9 mmol/L) at 12 months. Secondary efficacy outcomes include between group differences in stimulated C-peptide AUC at 24 months, time spent in target glucose range, glucose variability, hypoglycaemia and hyperglycaemia as recorded by periodically applied masked continuous glucose monitoring devices, total, basal and bolus insulin dose, and change in body weight. Cognitive, emotional and behavioural characteristics of participants and parents will be evaluated, and a cost-utility analysis performed to support adoption of CL as a standard treatment modality following diagnosis of T1D.ETHICS AND DISSEMINATION: Ethics approval has been obtained from Cambridge East Research Ethics Committee. The results will be disseminated by peer-reviewed publications and conference presentations.TRIAL REGISTRATION NUMBER: NCT02871089; Pre-results.

PMID: 32169925 [PubMed as supplied by publisher]

View post:
Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard...

By Jessica Hamzelou

Fei Maohua/Xinhua News Agency/PA Images

People who have the new coronavirus are most likely to die if they are older or show signs of sepsis or blood clotting problems. Thats according to a study that followed a small group of people infected with the covid-19 virus from diagnosis to hospital discharge or death.

Early on in the outbreak, two hospitals in Wuhan were designated to treat people who were infected with the new coronavirus. Until 1 February, people who were diagnosed with the virus in other hospitals were transferred to one of the two for care.

By January 31, 191 adults had been treated for the virus and either discharged or died at one of the two hospitals. Bin Cao at the China-Japan Friendship Hospital and Capital Medical University in Beijing, and his colleagues assessed these cases, looking for patterns in the characteristics of those who survived the virus and those who didnt.

Advertisement

The average age of these individuals was 56, and 62 per cent of them were men. Around half of them had underlying medical conditions most commonly high blood pressure and diabetes.

Of the 191 individuals, 137 were eventually discharged and 54 died. The average time from the onset of the illness to discharge from hospital was 22 days, the team say. Those that didnt survive the virus died an average of 18.5 days after symptoms began.

Death was more likely in people who already had diabetes or coronary heart disease. Older people were more likely to die, as were those showing signs of sepsis or blood clotting problems. Overall, more than half of those hospitalised with the virus developed sepsis.

Poorer outcomes in older people may be due, in part, to the age-related weakening of the immune system and increased inflammation that could promote viral replication and more prolonged responses to inflammation, causing lasting damage to the heart, brain and other organs, said study co-author Zhibo Liu at Jinyintan Hospital in Wuhan.

The team also found that people with covid-19 continue to shed the virus, and could potentially be able to infect others, for around 20 days, or until they die. The extended viral shedding noted in our study has important implications for guiding decisions around isolation precautions and antiviral treatment in patients with confirmed covid-19, said Cao.

Journal reference: The Lancet, DOI: 10.1016/ S0140-6736(20)30566-3

Sign up to our free Health Check newsletter for a round-up of all the health and fitness news you need to know, every Saturday

More on these topics:

Read the original post:
Coronavirus: Risk of death rises with age, diabetes and heart disease - New Scientist News

DUBLIN, March 9, 2020 /PRNewswire/ -- The "Disease Analysis: Type 1 Diabetes" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The research estimates that in 2018, there were approximately 46.6 million prevalent cases of type 1 diabetes in adults aged 20 years and over worldwide, and forecasts that number to increase to 51.8 million prevalent cases by 2027.

In children and adolescents aged below 20 years, there were approximately 1.08 million prevalent cases of type 1 diabetes worldwide in 2018, which are expected to increase to 1.12 million prevalent cases by 2027.

The overall likelihood of approval of a Phase I type 1 diabetes asset is 16.3%, and the average probability a drug advances from Phase III is 73.9%. Type 1 diabetes drugs, on average, take 8.5 years from Phase I to approval, which is the same as the average duration to approval in the overall endocrine space.

Despite the presence of multiple well-established products, the type 1 diabetes market is expected to see limited growth over the next decade. Future growth opportunities in the type 1 diabetes market are expected to be limited by its saturation with multiple maturing insulins, pricing pressures following the launches of biosimilars, and the expected failure of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to gain approval in the lucrative US market.

It is expected that patients will continue to switch from Novo Nordisk's Levemir to its successor product Tresiba due to the company's promotion of Tresiba's longer duration of blood sugar control compared to Levemir.

Likewise, Sanofi is pursuing a comparable commercial strategy to Novo Nordisk by promoting its next-generation insulin glargine product Toujeo over Lantus, as Lantus continues to lose patient share to the more affordable biosimilar Basaglar. However, key opinion leaders interviewed by the research analysts suggest that physicians are unconvinced that Toujeo possesses tangible benefits over biosimilar insulin glargine to justify its higher price.

Payers are severely restricting the use of specific insulin brands in the US. As the list price of insulins continues to increase, cost is becoming a strong determining factor for the choice of insulin treatment. Interviewed endocrinologists emphasized the impact of pricing on prescribing trends, as price fluctuations in the US lead to regular switching among patients.

Tresiba is forecasted to see the greatest uptake of all the long-acting insulin therapies in type 1 diabetes. Its long-acting duration of 42+ hours and its flexible dosing window (it can be administered at different times each day) offer improved convenience for patients, along with strong glycated hemoglobin (HbA1c) reductions. In addition, favorable pricing compared to Lantus and Toujeo within the US market is expected to drive growth of Novo Nordisk's market share.

The maturation of multiple short-acting insulin products has resulted in companies promoting switching to successor products with extended patent protection to maintain their diabetes revenues. Novo Nordisk's NovoLog will be facing biosimilar competition from Sanofi's SAR341402, therefore Novo Nordisk is actively encouraging patients to switch to NovoLog's successor ultra-rapid product Fiasp, which is positioned as having a faster onset of activity than NovoLog. Similarly, Eli Lilly has developed a faster-acting version of Humalog, ultra-rapid lispro, which is currently in preregistration in the US.

Increasing out-of-pocket costs for patients and competition from Sanofi's Admelog (a biosimilar of Humalog) have resulted in developers of branded products launching authorized generics in order to increase competitiveness in US government-insured patients, who must make co-payments based on a percentage of a drug's list price. In May 2019, Eli Lilly launched an authorized generic of Humalog at 50% of the list price of branded Humalog in hopes of maintaining government-insured patient share. This was followed in January 2020 by Novo Nordisk's launch of an authorized generic version of NovoLog, also at a 50% discount to the branded product.

Pipeline product teplizumab has shown promising potential to prevent or delay the onset of type 1 diabetes, as Phase II data have demonstrated that a single course of the drug significantly delayed disease onset in at-risk patients by a median of two years. The data will support a planned rolling Biologics License Application (BLA) submission for the prevention or delay of type 1 diabetes in H1 2020, and the review process will be fast tracked due to breakthrough therapy designation granted by the US Food and Drug Administration (FDA). However, if approved, teplizumab is likely to face two challenges when attempting to enter the market, the first of which is appropriately pricing the product to reflect the market value of delaying or preventing diabetes while ensuring that a high upfront cost does not prevent reimbursement. Indeed, achieving widespread reimbursement will be particularly challenging given the lack of a currently approved comparator and the fact that the mean duration of any delay in the onset of diabetes may not be known at the time of approval. The second challenge is the lack of existing screening programs to detect patients that are at risk for type 1 diabetes, which could severely limit the drug's target population (at least initially). Teplizumab's commercial success will therefore require healthcare services, physicians, and industry to collaborate on creating and integrating accessible screening programs into different health services globally.

Lexicon continues to pursue first-to-market status for Zynquista for type 1 diabetes in the US, and launched an appeal against the FDA's initial complete response letter (CRL), but this was unsuccessful. Thus, the company has now appealed to the Center for Drug Evaluation and Research, and is expecting a final judgment to be made in February 2020, but we expect this will also fail given that no new trial data have been added to the NDA to allay safety concerns and Lexicon has stated it does not wish to initiate further studies. An FDA decision on Jardiance's supplementary New Drug Application (sNDA) is expected in late Q1/early Q2, but a rejection is widely expected given the Endocrinologic and Metabolic Drugs Advisory Committee panel voted 14-2 against approval in November 2019. While SGLT-2 inhibitors may offer benefits to type 1 diabetes patients beyond improved glycemic control (namely blood pressure reduction and weight loss), our base case is that the class will not gain FDA approval for type 1 diabetes without additional studies to further investigate the risk of diabetic ketoacidosis (DKA) and the effectiveness of proposed risk-management strategies, and thus far none of the companies have publicly announced any intention to conduct such studies.

Key Topics Covered:

1. OVERVIEW

Story continues

2. DISEASE BACKGROUND

3. TREATMENT

4. EPIDEMIOLOGY

5. MARKETED DRUGS

6. PIPELINE DRUGS

7. KEY REGULATORY EVENTS

8. PROBABILITY OF SUCCESS

9. LICENSING AND ASSET ACQUISITION DEALS

10. CLINICAL TRIAL LANDSCAPE

11. DRUG ASSESSMENT MODEL

12. MARKET DYNAMICS

13. FUTURE TRENDS

14. CONSENSUS FORECASTS

15. RECENT EVENTS AND ANALYST OPINION

16. KEY UPCOMING EVENTS

17. KEY OPINION LEADER INSIGHTS

18. UNMET NEEDS

19. BIBLIOGRAPHY

20. APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/b9zitm

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2020-disease-analysis-on-type-1-diabetes---licensing-and-asset-acquisition-deals-301019775.html

SOURCE Research and Markets

Continued here:
2020 Disease Analysis on Type 1 Diabetes - Licensing and Asset Acquisition Deals - Yahoo Finance

More than 100 million people in the United States have diabetes or prediabetes.

Its also estimated that more than 100 million Americans have high blood pressure.

Those numbers have been rising, but researchers say there is a free and relatively easy way to reduce your risk of developing one of these diseases.

Its the simple act of walking.

The standard recommendation for physical fitness is 10,000 steps a day.

But even a fraction of that can work, according to the authors of a new study.

The researchers state that middle-aged study participants who walked the most steps per day over an average of 9 years had a 43 percent lower risk of diabetes and a 31 percent lower risk of high blood pressure.

The research was presented today at the American Heart Associations Epidemiology and Prevention/Lifestyle and Cardiometabolic Health Scientific Sessions 2020 in Phoenix, Arizona.

The benefits of exercise, specifically walking, have been studied extensively the past several years, David DaPrato, DPT, who works in sports rehabilitation and is a professional triathlon coach, told Healthline. There is good reason behind getting your 10,000-plus steps in each day.

The study was based on data from 1,923 participants in the national Coronary Artery Risk Development in Young Adults (CARDIA) study.

In addition to their overall conclusions, the researchers also reported that every set of 1,000 steps taken daily over the course of 9 years lowers the risk of obesity by 13 percent in middle-aged women.

In the study, participants wore accelerometer devices to measure physical activity at least 10 hours a day for at least 4 days.

The average age of the participants was 45. Almost 60 percent were women and about 40 percent were black.

The average follow-up time was 9 years.

Those with the highest step count were 61 percent less likely to have obesity, compared to women who walked the least.

The study didnt show any association between a lower risk of obesity and the number of daily steps walked by men.

Many people think that walking is not considered exercise and that walking on a daily basis is not enough to have a positive effect on your physical and mental health, said Cyrus Khambatta, PhD, the co-founder of Mastering Diabetes, an online coaching program helping people with diabetes reverse insulin resistance. For people with diabetes, even a short 30-minute walk before or after a meal has profound impact at lowering your blood glucose levels.

The 10,000 step benchmark goes back to 1965 when a Japanese scientist reportedly responded to the fitness craze surrounding the 1964 Tokyo Olympics by inventing the pedometer.

It was called the Manpo-kei, which translates to 10,000-steps meter.

It sounded like a semi-lofty but achievable goal. And it stuck.

Of course, there can be variations to all those steps.

My recommendation is 4,000 to 8,000 steps, but quality matters. Four thousand steps out in the countryside going up and down hills may give better health benefits compared to 8,000 steps in a mall. But its still better than nothing, said Sarah Sato, a nurse practitioner specializing in diabetes who recommends daily steps to her clients.

We see lovely, whole-person changes when someone starts walking regularly, Sato told Healthline. People often find their sleep improves, their mood can be more stable, and their digestion can become more regular.

Khambatta said the extra benefits can go even further.

Most people think that walking is only for their heart and diabetes but being active can also improve blood flow to your brain, which improves cognition, he told Healthline. Studies show that taking more steps on a daily basis can also reduce depression and anxiety. Given an increasing number of people diagnosed with mental health disorders, walking is a simple way to dramatically improve your mental health for free and can also be a social activity at the same time.

DaPrato says to start slowly and your body will adapt. And you may be grateful later when the cold and flu season comes.

After some time of consistent walking usually 3 or 4 weeks (what was) stress is now not so concerning to the body and is considered normal, he said. The body has adapted. So, since either exercise or a foreign bacterium is considered a stressor, the body more efficiently responds to invading bacteria once the tissues have adapted to exercise. This is why individuals who exercise regularly dont get sick as often.

Beth Auguste, a fitness trainer and registered dietitian, said walking gets blood to where it needs to go.

Imagine a credit card. Now imagine trying to tear it in half. You cant, she said. Now, imagine that you bend that credit card backward and forward multiple times. High blood pressure is often the result of stiff blood vessels. When you take a walk, your body needs to get more blood to your muscles quickly. If you think about your veins as similar to a hose, this means that the pressure will be increased. And, in the short term, this is a great thing. Your blood is pumping faster and harder and that increased pressure will have a similar effect on your veins, as the credit card. The frequent recurring pressure and release against the walls of your blood vessels may help to create a loosening effect, leading to more relaxed blood vessels and a lower resting blood pressure.

Mimi Secor, DNP, FNP-BC, FAANP, FAAN, is a family nurse practitioner and author of Debut a New You: Transforming Your Life at Any Age.

She said the habit of walking is more important than the intensity. Among her recommendations on how to incorporate more walking into ones life:

View original post here:
Daily Steps Can Reduce Risk of Diabetes and High Blood Pressure - Healthline

There is a significant correlation between type 2 diabetes mellitus and chronic kidney disease (CKD); up to 40% of patients with diabetes develop CKD as a direct result of diabetic complications. Patients with CKD have a need for a disease-specific diet, making management of diabetes challenging. Patients with CKD also face increased risk of complications associated with malnutrition, necessitating dietary needs and nutritional requirements tailored to individual patients.

Researchers led by Nourhan Khaled Hassan, MD, recently conducted a systematic review to examine nutritional requirements for patients with type 2 diabetes and chronic renal failure. The researchers screened 85 articles; of those, 22 were analyzed and included as per the study criteria. The data search included PubMed using medical subject headings terms, and a literature review through the Cochrane library and the British Medical Journal. Results were reported online in Current Diabetes Reviews [doi:10.2174/15733998166662000211120402].

The review highlighted nutrients and minerals needed to be maintained within a specified range defined by a patients needs and conditions. Dietary restrictions to prevent disease progression were also necessary. Patients receiving hemodialysis required vigorous monitoring of blood glucose levels as well as strict management of dietary intake. Risk-to-benefit ratios were utilized to determine optimal protein intake in patients on hemodialysis.

Dietary requirements should be individualized based on the patients disease severity and progression. Assessment of the patients previous and current diet, as well as matching it with their dietary requirements and preferences is crucial, the researchers said.

Read more from the original source:
Nutritional and Dietary Requirements in Patients with Type 2 Diabetes and CKD - DocWire News

PURPOSE:

We investigated whether the relationship between diabetes and all-cause and CVD-related mortality differed between women with and withoutbreast canceramong a cohort drawn from the same source population.

We interviewed 1,363 women newly diagnosed withbreast cancerin 1996-1997, and 1,358 age-matched women withoutbreast cancer, to assess history of physician-diagnosed diabetes. All-cause (n=631) and CVD-specific mortality (n=234) was determined by the National Death Index through 2009. We estimated multivariable-adjusted hazard ratios (HRs) for the rates of all-cause and CVD-specific mortality and, to account for competing causes of death, and subdistribution HRs (sHRs) for risk of CVD-related death.

Among women with and withoutbreast cancer, respectively, diabetes was associated with: all-cause mortality [HR (95% CI) 1.52 (1.13, 2.05) and 2.17 (1.46, 3.22)]; CVD-specific deaths [1.74 (1.06, 2.84) and 2.06 (1.11, 3.84)]; and risk of CVD-related death [sHR 1.36 (0.81, 2.27) and 1.79 (0.94, 3.40)]. Differences in effect estimates between women with and withoutbreast cancerdid not reach statistical significance (p-interaction>0.10).

We found that the positive association between a history of physician-diagnosed diabetes and risk of all-cause and CVD-related mortality is of similar magnitude among a population-based cohort of women with or withoutbreast cancer.

Go here to see the original:
Diabetes and Cardiovascular Disease Mortality Among A Population-Based Cohort of Women with and Without Breast Cancer - DocWire News

Research over the last decade has considered the potential role of gut microbiota in the development of obesity and its related metabolic disorders. Although initial findings in mice showing the relevant contribution of gut microbiota to weight change have not been translated in a straightforward way in humans, scientists hypothesize that gut microbes may help us understand the effectiveness of weight-loss strategies such as diet and bariatric surgery.

Kaplans group experiments in mice were among the first to find that changes in gut microbiota composition could account for some of the weight loss that happens after a gastric bypass. Although it seems microbes work by allowing animals to burn more energy, how exactly an altered intestinal microbiota might cause weight loss and metabolic improvements remains to be seen.

New research in obese diabetic women shows that gut microbiota composition before Roux-en-Y gastric bypass is linked to postoperative type 2 diabetes remission.

The authors sought to explore to what extent metabolic benefits after Roux-en-Y gastric bypass (RYGB) are related to gut microbiota profile in obese diabetic women.

Anthropometric and body composition variables improved up until 12 months after surgery. More interestingly, preoperative gut bacteria composition at the genus level differed between patients with and without T2D remission after surgery (57% versus 43%). Total type 2 diabetes remission after RYGB (assessed according to American Diabetes Association criteria) was associated with specific gut microbiota signatures before surgery. Those microbiota changes consisted of lower levels of Asaccharobacter and Atopobium and higher levels of Gemella, Coprococcus, and Desulfovibrio.

Specifically, the preoperative abundance of 10 gut bacteria genera correlated with the type 2 diabetes remission status, showing good sensitivity and specificity.

According to Karina Al Assal, one of the studys lead authors, These findings show that we can predict who is going to remit T2D before the surgery using the gut microbiota profile as a biomarker. This signature, if confirmed, may enable the prediction of future remission state of T2DM.

By contrast, postoperative changes in the relative abundance of gut bacteria and their richness were observed regardless of whether participants showed T2D remission or not.

The authors also reported some correlations between gut microbiota richness (defined as the number of species in fecal samples, without taking into account the abundance of each one) and food intake based on a 7-day record. For instance, before surgery, gut microbiota richness showed a positive correlation with fiber intake and inverse association with lipid intake, with the latter persisting until 12 months after surgery.

Although limited in sample and despite the quasi-experimental design of the study, these findings show that improvements in body and metabolic parameters secondary to RYGB surgery may be partly explained by gut microbiota composition.

Regarding how these findings might impact on clinically managing obesity in the foreseeable future, Karina Al Assal highlighted to GMFH editors via email that the study of gut bacteria signatures at the preoperative period in obese patients might pave the way for using gut microbiota as a marker to help clinicians when deciding on whether to recommend bariatric surgery. Likewise, based on associations found between gut bacteria and food intake, adding fibers and reducing lipid intake might improve the outcome of bariatric surgery.

Reference:

Al Assal K, Prifti E, Belda E, et al. Gut microbiota profile of obese diabetic women submitted to Roux-en-Y gastric bypass and its association with food intake and postoperative diabetes remission. Nutrients. 2020; 12, 278. doi: 10.3390/nu1202278.

Read the original:
Gut microbiota composition tied to type 2 diabetes remission following bariatric surgery in obese diabetic women - Gut Microbiota for Health

Diabetes mellitus (DM) plays an important role in restenosis and late in-stent thrombosis (ST).The current study using optical coherence tomography (OCT) aims to compare target lesion neointima in patients with or without diabetes after zotarolimus-eluting stent (ZES) treatment.OCT images of 90,212 struts and quantitative coronary angiography (QCA) in 62 patients (32 with DM and 30 without DM) with 69 de novo coronary lesions (34 DM and 35 non-DM) both after ZES implantation and 121month angiographic follow-up were recorded. Patient characteristics, lesion characteristics, clinical outcomes, and OCT findings including neointimal thickness, coverage, malapposition, and intimal morphology were analyzed.Baseline patient characteristics and lesion characteristics data were similar between the two groups. Higher neointimal thickness (0.140.09mm vs. 0.090.04mm, p=0.021), more neovascularization (3.036.24 vs. 0.521.87, p=0.017) and higher incidence of layered signal pattern (12.1919.91% vs. 4.289.02%, p=0.049) were observed in diabetic lesions comparing with non-diabetic lesions. No differences were found in malapposition, uncovered percentage, and thrombus between the two groups (all p>0.05). Occurrence of clinical adverse events was also similar during the follow-up period (p>0.05).Although more neointimal proliferation and more neovascularization were found in diabetic coronary lesions whencompared with non-diabetic lesions, treatment with ZES showed similar stent malapposition rate at 1-year follow-up. The data indicated that ZES treatment could possibly beeffective in treating diabetic coronary lesions.ClinicalTrials.gov identifier, NCT01747356.

Here is the original post:
Efficacy of Zotarolimus-Eluting Stents in Treating Diabetic Coronary Lesions: An Optical Coherence Tomography Study. - Physician's Weekly

The report on Diabetic Care Market offers an in-depth analysis of market trends, drivers, restraints, opportunities, etc. Along with qualitative information, this report comprises the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global Diabetic Care Market is segmented on the basis of type, application, and geography.

The report researches into the Diabetic Care market to evaluate its current and future potential. It leverages historical statistics about the Diabetic Care market, data from various other websites and sources, and inputs by the experts of the industry. It focuses completely on analyzing the regional subdivisions of the Diabetic Care markets.

Global Diabetic Care market is estimated to reach $112.2 Million by 2025; growing at a CAGR of 6.23% till 2025.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): https://www.esticastresearch.com/report/global-diabetic-care-market/#request-for-sample

Competitive Landscape

Key Players in this showcase are:

AstraZeneca Pharmaceuticals LPBristol-Myers Squibb CoDexcom, Inc.Eli Lily and CompanyJohnson & Johnson Services, Inc.MedtronicNovo Nordisk A/SRoche Diagnostics LtdSanofi S.A.Terumo Europe NV

Diabetic Care showcasing different procedures and strategies, providers and merchants working in the Diabetic Care market, investigates components convincing Diabetic Care market development, generation patterns, and following systems. The overall Diabetic Care market report performs SWOT examination and PESTEL Diabetic Care investigation to uncover the steadiness, imperfections, openings, and dangers in the Diabetic Care industry. Moreover, it thinks about the earlier years information to see the deterrents looked by new players in the Diabetic Care market universally, the danger from other administrations or items, and the general showcase limit of the aggressive players.

Global Diabetic Care Market Segmentation:

The Diabetic Care Market report also covers segment analysis, including product type, application, and region, etc. cover different segment market sizes, both volume, and value.

Global Diabetic Care market segmentation:

By Type

Youth Onset DiabetesAdult Onset DiabetesGestational DiabetesBy End-User

Research InstituteHospitalHome Care

Click to access full report andTable of Content and Figures @ https://www.esticastresearch.com/report/global-diabetic-care-market/#table-of-content

Global Diabetic Care market segmentation by Geography:

The estimates for all segments including type and application have been provided on a regional basis for the forecast period mentioned above. We have implemented a mix of top-down and bottom-up approaches for market sizing, analyzing the key regional markets, dynamics, and trends for various applications. The Global Diabetic Care market has been estimated by integrating the regional markets.

Latitude of the Diabetic Care Market report is as follows:

Request Customization or Discount of This Report @ https://www.esticastresearch.com/report/global-diabetic-care-market/#customization

Reasons to buy Diabetic Care Market Report:

Esticast Research is a research firm providing research reports on various industries with a unique combination of authenticity, extensive research, and infallibility. We provide syndicated market research reports, customization services, and consulting services to help businesses across the world in achieving their goals and overcoming complex challenges. We specialize in providing 360 degree view of the markets to assist clients in determining new opportunities and develop business strategies for the future with data and statistics on changing market dynamics. Esticast Research & Consulting has expert analysts and consultants with an ability to work in collaboration with clients to meet their business needs and give opportunities to thrive in a competitive world. A comprehensive analysis of industries ranging from healthcare to consumer goods and ICT to BFSI is provided by covering hundreds of industry segments. The research reports offering market forecasts, market entry strategies, and customer intelligence will help clients across the world in harnessing maximum value on their investment and realize their optimum potential..

Get In Touch!Esticast ResearchNavale ICON IT Park,Office No. 407, Mumbai Bangalore Highway, Narhe, PuneUSA:+1-213-275-4706IND+91-844-601-6060Email:[emailprotected]

See the article here:
Diabetic Care Market by Type (Youth Onset Diabetes, Adult Onset Diabetes, and Gestational Diabetes), By End-User (Research Institute, Hospital, and...

Published: 3/8/2020 6:31:19 PM

Nearly $713,000 in federal funding is going to Dartmouth College to support research to test new ways to better treat and control type 1 diabetes.

The funding will go toward a five-year study that will use digital tools to support behavioral changes to help young people with diabetes follow a complicated medical regimen and achieve better health outcomes.

It will be distributed by the National Institute of Diabetes and Digestive and Kidney Diseases, which is part of the National Institutes of Health.

The funding was announced recently by New Hampshires congressional delegation.

Research like this can help to improve quality of life and, ultimately, medical outcomes for countless patients, U.S. Sen. Maggie Hassan said in a statement.

The funding to Dartmouths Center for Technology and Behavioral Health will go toward a study led by Dr. Catherine Stanger.

I am grateful to the NIH for their support of this work since 2012, and look forward to leading this national project, where we will reach out directly to young adults with type 1 diabetes to support them in learning to better manage this complex and challenging condition, said Stanger said.

Associated Press

See the original post here:
More than $700K to go toward type 1 diabetes research - Concord Monitor

HOUSTON Pain, numbness and tingling in your hands and feet can be a sign you have neuropathy or nerve damage. Common treatments include pain medication, injections, or tens (an electrical stimulator), but Dr. Bao Thai from Advanced Nerve and Health Center says these treatments aren't effective for neuropathy.

Dr. Thai has developed a non-invasive, pain free treatment that helps the body repair nerves without surgery or medication. Patients are seeing amazing results.

Dr. Thai is a pioneer in this field, and has studied all over the world exploring technologies and processes. Through his own research, he found the body wants to heal the nerve, and over time it will heal.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $27, the first 17 callers will get an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if they can help. This is a $399 value.

Call Advanced Nerve and Health Center now at 832-626-1260.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

For more information, log on to NerveAndHealth.com.

This content is sponsored by: Advanced Nerve and Health Center

See the rest here:
Reverse symptoms of diabetic neuropathy with life-changing treatment - KHOU.com

As the number of UK cases of coronavirus continues to rise, what has become clear is how many of the patients to die from the virus have underlying health conditions that make them susceptible to catching it.

Thethird person in the UK to die, after testing positive for the coronavirus upon his return from Italy, was being treated at the North Manchester General Hospital for underlying health conditions when he died.

The UKs second death was a man in his early 80s, who also had underlying health issues, as did the woman in her 70s who became the UKs first death linked to the virus.

Its a new infection, but from our experience with dealing with flu epidemics, we know that people with various conditions will fare worse, says Fan Chung, a professor of respiratory medicine at Imperial College. A paper has just published in the New England Journal of Medicine, that looked at the first 1,001 cases in Wuhan. The figures showed those with diabetes, high blood pressure, heart disease, COPD, cancer and renal disease, fared worse. And I suspect the people who very unfortunately died in the UK had one or any of those conditions."

A Chinese study hasfound people with heart disease, diabetes and cancer had a 79 per cent chance of being admitted to intensive care or dying from the virus, due to their weakened immune systems.

Here are the underlying health conditions that put you at higher risk of getting the coronavirus a reminder of how it might initially spread.

People with diabetes face a higher risk of complications if they get the coronavirus, due to the fact their fluctuating or elevated glucose levels leave them with lowered immunity. This also means they have less protection against getting the virus. Coronavirus or COVID-19 can cause more severe symptoms and complications in people with diabetes, says Dan Howarth from Diabetes UK. If you have diabetes and you have symptoms such as a cough, high temperature and feeling short of breath you need to monitor your blood sugar closely and call the NHS 111 phone service.

People with diabetes who dont experience symptoms and have recently travelled to any of the affected areas need to follow information on the NHS and theGOV.UKwebsites, adds Howarth. "These are updated regularly and are the most up-to-date source of information available.

Its believed around 40 per cent of hospitalised coronavirus patients have heart disease. Somebody with a heart condition is more likely to have a compromised immune system, so their immune response wont be as strong if exposed to a virus. COVID-19 also targets the lungs, which could cause problems for a diseased heart that has to work harder to get oxygenated blood around the body.

Asthma is a respiratory condition that leads to inflammation of the breathing tubes that transport air to and from the lungs.Coronavirus can cause respiratory problems for anyone, but for the 5.4million people in the UK with asthma, the risk is greater, says Jessica Kirby, Head of Health Advice at Asthma UK. Respiratory viruses like thiscan triggerasthma symptoms and couldlead to anasthma attack.

Kirby says if youre a sufferer, itsessential to takeyour preventer, daily as prescribed. This helps cut the risk of an asthma attack being triggered by any virus, including coronavirus, she says. Keeping a reliever inhaler to handis vital, soyoucan use it ifyou get asthmasymptoms.

Ifyourasthma symptomsgetworse, and you havent travelled to an at-risk area or been in contact with someone who has, make an appointment to see your GP as soon as you can. If you think you might have coronavirus, use the NHS 111 online coronavirus service."

COPD is the name for certain lung conditions that cause breathing difficulties, including emphysema, which is characterised by damage to the air sacs in the lungs,and chronic bronchitis, which is a long-term condition involving inflammation of the lungs airways. People with COPD are more likely to get coronavirus if exposed to the virus because they have damage to their epithelial lining, which makes it easier for viruses to enter the body.

Cancer patients are more susceptible due to their compromised immune system. Various cancer drugs and treatments, like chemotherapy, mean your immune system may be suppressed, says Prof Chung, and this would increase your chances of catching it. And if you do get it while you havecancer, you would probably fare worse than somebody with the virus who didnt have cancer.

Not a health condition as such, but many of the thousands of deaths so far have involved elderly people with underlying health conditions. The elderly are at greater risk, and government advice for the elderly to avoid crowded areas is sound advice, says Prof Chung. The figures we have so far seem to imply the risk increases above the age of 70. However its even worse for those over 80. The chances of getting it and faring worse increase two or three times above the age the 70, but even more so above 80.

In terms of children, who appear to be less prone to getting the coronavirus and, if they do, getting a more benign version of the illness, Prof Chung says that a young person with an underlying health condition isn't at a greater risk: A young person with asthma, or heart disease, wouldnt be predisposed to get the coronavirusor suffer from it, in the same way an adult with the condition would, he says. Maybe its their immune system, and how its different from older people, but in terms of their susceptibility of getting the coronavirus, health conditions in young people dont seem to increase their chances of catching it.

Read the original here:
The underlying health conditions which affect how you cope with the coronavirus - Telegraph.co.uk

What is diabetes?

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycaemia, or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body's systems, especially the nerves and blood vessels.

In 2014, 8.5% of adults aged 18 years and older had diabetes. In 2016, diabetes was the direct cause of 1.6 million deaths and in 2012 high blood glucose was the cause of another 2.2 million deaths.

Type 1 diabetes (previously known as insulin-dependent, juvenile or childhood-onset) is characterized by deficient insulin production and requires daily administration of insulin. The cause of type 1 diabetes is not known and it is not preventable with current knowledge.

Symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes, and fatigue. These symptoms may occur suddenly.

Type 2 diabetes (formerly called non-insulin-dependent, or adult-onset) results from the bodys ineffective use of insulin. Type 2 diabetes comprises the majority of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity.

Symptoms may be similar to those of type 1 diabetes, but are often less marked. As a result, the disease may be diagnosed several years after onset, once complications have already arisen.

Until recently, this type of diabetes was seen only in adults but it is now also occurring increasingly frequently in children.

Gestational diabetes is hyperglycaemia with blood glucose values above normal but below those diagnostic of diabetes, occurring during pregnancy.

Women with gestational diabetes are at an increased risk of complications during pregnancy and at delivery. They and their children are also at increased risk of type 2 diabetes in the future.

Gestational diabetes is diagnosed through prenatal screening, rather than through reported symptoms.

Impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) are intermediate conditions in the transition between normality and diabetes. People with IGT or IFG are at high risk of progressing to type 2 diabetes, although this is not inevitable.

Over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves.

Simple lifestyle measures have been shown to be effective in preventing or delaying the onset of type 2 diabetes. To help prevent type 2 diabetes and its complications, people should:

Early diagnosis can be accomplished through relatively inexpensive testing of blood sugar.

Treatment of diabetes involves diet and physical activity along with lowering blood glucose and the levels of other known risk factors that damage blood vessels. Tobacco use cessation is also important to avoid complications.

Interventions that are both cost-saving and feasible in developing countries include:

Other cost saving interventions include:

WHO aims to stimulate and support the adoption of effective measures for the surveillance, prevention and control of diabetes and its complications, particularly in low and middle-income countries. To this end, WHO:

The WHO "Global report on diabetes" provides an overview of the diabetes burden, the interventions available to prevent and manage diabetes, and recommendations for governments, individuals, the civil society and the private sector.

The WHO "Global strategy on diet, physical activity and health" complements WHO's diabetes work by focusing on population-wide approaches to promote healthy diet and regular physical activity, thereby reducing the growing global problem of overweight people and obesity.

* Defined as fasting blood glucose equal to or higher than 7 mmol/L, or on medication for raised blood glucose, or with a history of diagnosis of diabetes.

** High blood glucose is defined as a distribution of fasting plasma glucose in a population that is higher than the theoretical distribution that would minimize risks to health (derived from epidemiological studies). High blood glucose is a statistical concept, not a clinical or diagnostic category.

(1) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration.

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio et al. Lancet. 2010; 26;375:2215-2222.

(2) Causes of vision loss worldwide, 1990-2010: a systematic analysis.Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H et al. Lancet Global Health 2013;1:e339-e349

(3) 2014 USRDS annual data report: Epidemiology of kidney disease in the United States.United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014:188210.

Read this article:
Diabetes - World Health Organization

Oranges could be great for losing weight, study suggests (Getty Images)

Eating oranges could be the route to losing weight, staying slim and preventing diabetes, new research has found.

This works due to a chemical found in oranges and tangerines called nobiletin.

Nobiletin may even have the ability to reverse obesity and unclog arteries.

In the experiment by the University of Western Ontario, mice were fed the substance and turned out to be leaner and healthier as a result.

The researchers are now conducting the same experiment using humans.

Read more: Waist circumference is vital sign and should be measured

Dr Murray Huff, who has been studying nobiletin's effects for over a decade, was pleased with the research.

We've shown that in mice that already have all the negative symptoms of obesity, we can use nobelitin to reverse those symptoms, and even start to regress plaque build-up in the arteries, known as atherosclerosis.

This means that nobelitin could be essential in reversing symptoms of obesity in its tracks.

How this super compound works is still shrouded in mystery, though.

The researchers originally thought the molecule was likely acting on the pathway that regulates how fat is handled in the body, called AMP Kinase.

This enzyme turns on the machinery in the body that burns fats to create energy, and it also blocks the manufacture of fats.

However, during further tests on mice without AMP Kinase, the nobiletin still had a positive affect.

Read more: Four in five children arent exercising enough, WHO finds

While the way nobiletin is working in the body remains a mystery, Dr Huff was pleased that it didnt work through AMP Kinase.

It shows that nobiletin won't interfere with other drugs that act on the AMP Kinase system, which currently include diabetes medicines like metformin.

The team will now move onto trialling this on human beings.

If its successful, this could provide us with a beneficial way to tackle obesity - a major burden to the healthcare system.

Obesity and its resulting metabolic syndromes are a huge burden to our health care system, and we have very few interventions that have been shown to work effectively.

We need to continue this emphasis on the discovery of new therapeutics.

The rest is here:
Eating oranges may be the key to losing weight, study finds - Yahoo News

By Tanya Caylor

Type 1 diabetes is increasing at a rate of 3 percent per year. Cases of rheumatoid arthritis are rising only slightly less quickly, at least among women, at a rate of 2.5 percent per year. Celiac disease is four times more common now than half a century ago.

What do these statistics have in common? All three are part of an overall increase in autoimmune disorders, which now affect more than 23 million Americans and rank as the third most common type of chronic illness, surpassed only by heart disease and cancer. Scientists have identified at least 80 distinct types of disease in which the body seemingly turns on itself, attacking its own tissue. While the three mentioned above are among the most common, researchers suspect there may be dozens more yet to be discovered.

Though the exact cause of autoimmune disease, in all its many forms, remains unknown, it is suspected that a virus or something in the patients environment interacts with a susceptible set of genes to generate an immunological false alarm. Diet has come under increasing scrutiny in recent years. Some studies on type 1 diabetes, for instance, indicate that a Vitamin D deficiency may be involved, while others point to cows milk products in infancy as playing a possible role. The natural food additive carrageenan, derived from seaweed and increasingly used as a thickening agent in some dairy products, has been linked to an increase in the presence of glycosaminoglycans in the body. A 2015 study suggested these naturally occurring complex carbohydrates may be connected to rheumatoid arthritis. The additive is also under scrutiny by the National Institutes of Health for causing gastrointestinal inflammation potentially related to multiple autoimmune disorders. Both carrageenan and gluten, the protein found in wheat and barley that appears to trigger Celiac disease, are among seven types of food additives that have been linked to an overall increase in autoimmune diseases.

A study published in the June 2015 issue of the journal Autoimmune Reviews singles out sodium, glucose, gluten, emulsifiers (such as carrageenan), organic solvents (such as benzene and hexane), nanometric particles and microbial transglutaminase (an enzyme that acts as a protein glue) as increasing susceptibility to autoimmune diseases by damaging the protective barrier in the bowels designed to keep harmful toxins and bacteria out of the bloodstream.

Note that not all of the food additives are industrial in nature. Sugar and salt, for instance, are common ingredients in foods prepared at home. However, even in their most familiar form, sugar and salt help to increase food absorption. Both can take on more industrialized forms in factory-processed foods. And both have been shown, along with the other additives on the list, to increase intestinal permeability resulting in entry of foreign immunological antigens and activation of the autoimmune cascade.

Getting Past the Bodys Defenses

Noting that only a single layer of epithelial cells separates the luminal contents of the intestine from the effector immune cells, the authors detail literally dozens of biochemical stratagems for getting over, under, around and through the intercellular tight junction, a complex network of proteins that modulate movement of fluid, macromolecules and leukocytes from intestinal lumen to the bloodstream and vice versa. Though these potential breaches are collectively known in laymans terms as leaky gut, in some cases what happens is literally a case of reconfiguring the cellular structure of the sentries on duty.

Of most concern, perhaps, is the least predictable category of additive, known as nanometric particles. Initially used in the pharmaceutical industry as encapsulation devices designed to speed drug delivery into the bloodstream, they are increasingly being used in the food industry to enhance the taste and texture of foods. Trouble is, the rules of operation at the nanotechnology level are not well understood.

If an additives absorption into the body is increased substantially by encapsulating it within lipid nanoparticles, then it could exhibit toxic effects that could not be predicted from data obtained on the same material in microscopic or macroscopic form, write the authors, Dr. Aaron Lerner of the Technion-Israel Institute of Technology and Dr. Torsten Matthias of the Aesku-Kipp Institute in Germany. This is particularly true, they note, if the bioactive component is incorporated into a product that is consumed regularly in large volumes, such as artificially enhanced soft drinks or beverages.

In this study each food additive was studied separately using tissue samples in a lab setting. But in reality the interactions between the modern food supply and the human body is much more complex, the authors note, since in nanotechnology many of the additives can be combined.

The diet of the industrialized world is vastly different from what it was even a generation ago, write Lerner and Matthias, with new genetic modifications, chemical ingredients, flavors, preservatives and new nanotechnologies. Over recent decades, a significant increase in the incidence of autoimmune diseases in industrialized countries has led to the postulation that diet is a potential environmental risk factor for such disorders. Although causality has not been proven, increases in the usage of the abovementioned food additives have paralleled increased incidences of autoimmune diseases over the same amount of time.New Diagnostic Tools for An Evolving Dietary Universe

With changes occurring so quickly in the food industry, health professionals can have a hard time dispensing dietary advice. Even when patients have been advised what to look for, knowing what additives lurk in common foods may be increasingly tricky. Take microbial transglutaminase, the so-called meat glue that can turn random hunks of meat into what appears to be steak. According to the USDA, this enzyme is supposed to appear on the ingredient list of meat products, with the term formed meat product appearing on the label. But if meat glue is used in a restaurant or cafeteria which is increasingly the case customers would have a much harder time knowing what exactly they are cutting into.

Another problem facing modern health care professionals is the increasing evidence of overlap between autoimmune disorders. Though specific diseases have traditionally been treated by doctors who specialize in a particular branch of anatomy, the autoimmune cascade can ultimately entangle multiple systems within the body.

Visit link:
Diabetes Health Type 1: Food Additives Linked to Rise in Autoimmune Diseases - Diabetes Health

Liva Healthcare and Living Well Taking Control (LWTC) have won the contracts with Shropshire and Telford & Wrekin Clinical Commissioning Groups as part of the Healthier You: NHS Diabetes Prevention Programme (NHS DPP).

Liva Healthcare will offer a digital service to complement LWTCs face-to-face intervention programme.

Type two diabetes is one of the most significant healthcare challenges of our time.

There is strong evidence that its onset can be prevented with an improved diet, an increase in physical activity and successful weight loss.

The Healthier You programme was officially launched in 2016 to support people who have a high risk of developing type two diabetes.

The national roll-out of the NHS DPP programme over the last year has seen face-to-face providers supported by digital partners.

The service from Liva Healthcare and LWTC will be provided free of charge to patients at risk of type two diabetes through a referral from their GP.

About 5,000 patients are expected to be treated across Shropshire, Telford and Wrekin, and Dorset through it latest partnership, over the course of a year.

Liva Healthcare provides patients with access to a free, dedicated, personal health coach.

The regular coaching sessions, through an app, help patients tackle chronic conditions through sustainable lifestyle and behaviour changes.

LWTC is a limited liability partnership between Birmingham-based social enterprise Health Exchange CIC and Exeter-based charity Westbank Community Health and Social Care.

Each organisation has expertise in supporting individuals to change their lives by establishing new patterns of behaviour to improve their health and wellbeing.

The LWTC programme consists of 13 sessions across nine months.

They cover key topics such as understanding the risks of diabetes, behaviour change techniques, healthy lifestyles and mental wellbeing.

Rune Bech, co-founder and UK head of Liva Healthcare, said: We are seeing remarkable results from people going through Livas programme.

"Patients with chronic conditions like obesity, pre-diabetes or type two diabetes have been able to halt or even reverse their conditions simply by providing personal health coaching.

This unique relationship-based approach makes hard-won lifestyle changes long lasting and sustainable.

"By providing a digital solution, the Liva programme is scalable and cost-effective and supports health professionals to drive real change in their communities.

"This new partnership with the NHS and LWTC will help us help even more people live longer and better, which is why we go to work every morning.

Russell Muirhead, clinical director for LWTC said: Were pleased to be named as an NHS Diabetes Prevention Programme provider across Shropshire, Telford and Wrekin.

"Were now busy working in partnership with the local health economy to meet the needs of the local communities from day one.

"This is vital given that over 11,000 people across Shropshire, Telford and Wrekin are at high risk of developing type two diabetes.

"Our focus remains on recruiting passionate local coaches who care about their communities and making a real difference to peoples lives.

Read the original:
Organisations partner with Shropshire health groups to prevent type two diabetes - shropshirestar.com

New York, March 06, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Diabetic Footwear Market, By Product, By End User, By Distribution Channel, By Region, Competition, Forecast & Opportunities, 2025" - https://www.reportlinker.com/p05872172/?utm_source=GNW

Global diabetic footwear market is projected to reach $ 9.7 billion by 2025 on account of rising adoption of diabetic footwear as they are designed to minimize the risk of skin breakdown caused by poor circulation, neuropathy and foot deformities. Moreover, these footwears offer a variety of features like non-binding uppers, stretchable uppers, orthotic support, extra depth design for a pressure-free fit, deep-toe-box, functional soles, and others in order to protect diabetic feet. These designed footwears are mostly used by athletes and common people that are suffering from foot deformities caused by diabetes. Diabetes leads to poor control over blood sugar levels and thus can damage nerves and vessels of feet. Therefore, consumers with diabetes are more likely to have foot problems which are the key factor anticipated to influence the demand for diabetic footwear across the globe in the coming years. Rising prevalence of diabetes and growing disposable income are some of the major factors anticipated to propel the global diabetic footwear market in the coming years. However, the market growth is likely to be negatively affected on account of lack of proper knowledge about using diabetic footwear among potential users as well as low awareness about proper foot care in diabetic patients, particularly in underdeveloped and developing countries. The global diabetic footwear market is segmented based on the product, end-user, distribution channel and region.Based on the product, the market can be segmented into slippers, sandals and shoes.

Among them, the shoe footwear type dominated the market in 2019, and the product segment is expected to maintain its leadership position in the coming years as well which can be attributed to the higher preference of shoes in both men and women. Office going population always prefers wearing shoes since a formal attire includes shoe, which is increasing the demand for these shoes, thereby boosting the growth of this segment in the market. Major players operating in the diabetic footwear market are Podartis S.r.l., American Aetrex Worldwide, Inc., Orthofeet Inc, Drew Shoes (U.S.), Dr. Comfort, DJO Global Inc (U.S.), Dr. Zen Products, Inc. (U.S.), Propet USA, Inc. (U.S.), DARCO International, I-Runner (U.S.), Finn Comfort (U.S.), Pilgrim shoes (U.S.), Hush Puppies Retail, Inc., New Balance, Inc., and others.

Years considered for this report:

Historical Years: 2015-2018 Base Year: 2018 Estimated Year: 2019 Forecast Period: 20202025

Objective of the Study:

To analyze and forecast the market size of the global diabetic footwear market. To classify and forecast global diabetic footwear market based on the product, end-user, distribution channel, company and regional distribution. To identify drivers and challenges for the global diabetic footwear market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global diabetic footwear market. To conduct a pricing analysis for the global diabetic footwear market. To identify and analyze the profile of leading players operating in the global diabetic footwear market. The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of diabetic footwear manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the distribution channels and presence of all major players across the globe. The analyst calculated the market size of global diabetic footwear market by using a bottom-up approach, wherein data for various end-user segments were recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Diabetic footwear manufacturers, suppliers and other stakeholders Government bodies such as regulating authorities and policymakers Organizations, forums and alliances related to diabetic footwear Market research and consulting firms The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, the global diabetic footwear market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Market, By Product: o Shoes o Sandals o Slippers Market, By End User: o Men o Women Market, By Distribution Channel: o Store-based o Non-store based Market, By Region: o North America United States Mexico Canada o Asia-Pacific China Japan India South Korea Australia o Europe Germany France United Kingdom Italy Spain o South America Brazil Colombia Argentina o Middle East & Africa South Africa Saudi Arabia UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global diabetic footwear market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).Read the full report: https://www.reportlinker.com/p05872172/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
Global diabetic footwear market is projected to reach $ 9.7 billion by 2025 - GlobeNewswire

Tandem Diabetes Care, Inc. (TNDM) is priced at $75.44 after the most recent trading session. At the very opening of the session, the stock price was $75.43 and reached a high price of $76.81, prior to closing the session it reached the value of $77.58. The stock touched a low price of $72.92.

Tandem Diabetes Care, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $91.65 on 02/20/20, with the lowest value was $51.37 for the same time period, recorded on 04/18/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Tandem Diabetes Care, Inc. shares are logging -17.69% during the 52-week period from high price, and 46.86% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $51.37 and $91.65.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 948399 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Tandem Diabetes Care, Inc. (TNDM) recorded performance in the market was 26.56%, having the revenues showcasing 18.36% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.53B, as it employees total of 1043 workers.

During the last month, 9 analysts gave the Tandem Diabetes Care, Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 67.89, with a change in the price was noted +18.90. In a similar fashion, Tandem Diabetes Care, Inc. posted a movement of +33.43% for the period of last 100 days, recording 1,545,246 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for TNDM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Tandem Diabetes Care, Inc. in the period of last 50 days is set at 51.19%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.97%. In the last 20 days, the companys Stochastic %K was 32.85% and its Stochastic %D was recorded 35.90%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 26.56%. Additionally, trading for the stock in the period of the last six months notably improved by 7.83%, alongside a boost of 22.11% for the period of the last 12 months. The shares increased approximately by 7.84% in the 7-day charts and went down by 1.04% in the period of the last 30 days. Common stock shares were driven by 18.36% during last recorded quarter.

Continue reading here:
Here is why Tandem Diabetes Care, Inc. (TNDM) stock volatility recorded over the last month was 5.48% - The InvestChronicle

Brushing your teeth frequently may reduce your risk for diabetes, new research suggests.

Using Korean government health records and self-reports, researchers gathered health and behavioral data on 188,013 men and women, average age 53, who were free from diabetes. More than 17 percent had periodontal disease. Over the course of the 10-year study, 31,545 developed diabetes.

After controlling for age, sex, socioeconomic status, smoking, alcohol consumption, physical activity, lipid levels, hypertension and other factors, they found that people with periodontal disease had a 9 percent increased risk for developing diabetes. The study is in Diabetologia.

Compared with people who did not brush or brushed only once a day, those who brushed twice a day had a 3 percent reduced risk for diabetes, and those who brushed three times a day an 8 percent reduced risk. The loss of 15 or more teeth was associated with a 21 percent increased risk for developing diabetes.

Neither the number of visits to the dentist or the frequency of professional tooth cleaning was associated with the incidence of diabetes.

The lead author, Dr. Yoonkyung Chang, a professor of neurology at Ewha Womans University in Seoul, said that healthy lifestyle has more powerful effects on diabetes prevention than tooth brushing.

But, she said, Frequent tooth brushing reduces local inflammation and bacteremia, and if good brushing habits persist for a long time, this can affect systemic diseases.

The rest is here:
Frequent Tooth Brushing Tied to Lower Diabetes Risk - The New York Times